SCHEMBL4051334

SCHEMBL4051334

c1ccc(CCc2nc3ncc(-c4cccs4)cc3[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
RAB9A P51151 3/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CHEK1 O14757 1/20 0.41
PDE10A Q9Y233 1/20 0.40
GSK3B P49841 1/20 0.39
QPCT Q16769 2/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2B Q13224 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063023 0.89 GAA (0.43) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4058698 0.83 NOS3 (0.62) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4055025 0.82 SMN1; SMN2 (0.47) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4053685 0.81 SMN1; SMN2 (0.46) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL13608052 0.81 RAB9A (0.44) RAB9ANPC1MAPTALDH1A1SMN1; SMN2
SCHEMBL4049621 0.80 NOS3 (0.55) NOS3NOS1NOS2ALDH1A1SMN1; SMN2
SCHEMBL4051893 0.79 PRNP (0.44) RAB9ANPC1MAPTSMN1; SMN2CHEK1
SCHEMBL4053877 0.77 SMN1; SMN2 (0.47) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4054497 0.77 NOS3 (0.47) NOS3NOS1NOS2RAB9ANPC1
SCHEMBL4060650 0.76 NOS3 (0.49) NOS3NOS1NOS2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.